ImaRx Therapeutics is a biopharmaceutical company that specializes in creating treatments for vascular disorders related to blood clots. They have two primary programs: thrombolytics and sonoLysis. Their products have been approved by the US Food and Drug Administration (FDA) for conditions such as acute pulmonary embolism, which is a blood clot in the lungs. Founded in 1991, the company is based in Los Angeles, California.

Drugs associated with ImaRx Therapeutics, Inc.

MRX-951

Target

Tubulin

Mechanism

Tubulin inhibitors

Active Org.-

Originator Org.

ImaRx Therapeutics, Inc.

Active Indication-

Inactive Indication

Neoplasms

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

Alteplase/microbubble combination therapeutic(ImaRx Therapeutics)

Target

PLG

Mechanism

PLG stimulants

Active Org.-

Originator Org.

ImaRx Therapeutics, Inc.

Active Indication-

Inactive Indication-

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

MRX-952

Target-

Mechanism-

Active Org.-

Originator Org.

ImaRx Therapeutics, Inc.

Active Indication-

Inactive Indication

Epilepsy [+4]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with ImaRx Therapeutics, Inc.

EUCTR2006-005491-40-DE / Not yet recruitingNot Applicable

A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 with Continuous Ultrasound Administration in Subjects with Acute Ischemic Stroke Receiving Treatment with Intravenous Tissue Plasminogen Activator

Start Date10 Jul 2007

Sponsor / Collaborator

ImaRx Therapeutics, Inc.

NCT00504842 / TerminatedPhase 1/2

A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Start Date01 Dec 2006

Sponsor / Collaborator

ImaRx Therapeutics, Inc.

NCT00507806 / TerminatedPhase 1/2

Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke

The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

Start Date01 Mar 2005

Sponsor / Collaborator

ImaRx Therapeutics, Inc.

100 Clinical Results associated with ImaRx Therapeutics, Inc.

0 Patents (Medical) associated with ImaRx Therapeutics, Inc.

Literatures (Medical) associated with ImaRx Therapeutics, Inc.

01 Nov 2014·Journal of Stroke and Cerebrovascular DiseasesQ4 · MEDICINE

Comparison of Sonothrombolysis Efficiencies of Different Ultrasound Systems

Q4 · MEDICINE

Article

Author: Zhou, Yufeng ; Ramaswami, Rajan

BACKGROUNDStroke is a severe emergent cardiologic disease for death and permanent disability. Ultrasound exposure could noninvasively enhance the clot lysis of tissue plasminogen activator (tPA) with the presence of microbubbles (MBs). A variety of sonography systems are available in the market, and whether sonothrombolysis is only successful using specific devices is unknown.METHODSThree commercial ultrasound systems (Siemens, Philips, and SonoSite) were characterized first for their acoustic field, and then the thrombolysis efficiencies were evaluated using the same in vitro setup and protocol.RESULTSDespite different acoustic fields and pressure waveforms at the focus, similar sonothrombolysis abilities with tPA and MBs were found, and the presence of temporal bone will worsen the performance slightly (by about 10% in the clot lysis).CONCLUSIONSTherefore, it suggests that satisfactory sonothrombolysis in vivo or in clinics could be achieved using a variety of commercial ultrasound devices if the acoustic output is sufficiently strong.

01 Jul 2009·Annals of NeurologyQ1 · MEDICINE

Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial

Q1 · MEDICINE

Article

Author: Marta Rubiera ; Evan C. Unger ; Carlos A. Molina ; Paul Sierzenski ; Walter Singleton ; Peter D. Schellinger ; Robert Mikulik ; Greg Pate ; Marc D. Malkoff ; Nicole R Gonzales ; James C. Grotta ; Georgios Tsivgoulis ; Andrew D Barreto ; Garen Manvelian ; Andrei V. Alexandrov ; James Ostrem

AbstractObjectiveMicrospheres (μS) reach intracranial occlusions and transmit energy momentum from an ultrasound wave to residual flow to promote recanalization. We report a randomized multicenter phase II trial of μS dose escalation with systemic thrombolysis.MethodsStroke patients receiving 0.9mg/kg tissue plasminogen activator (tPA) with pretreatment proximal intracranial occlusions on transcranial Doppler (TCD) were randomized (2:1 ratio) to μS (MRX‐801) infusion over 90 minutes (Cohort 1, 1.4ml; Cohort 2, 2.8ml) with continuous TCD insonation, whereas controls received tPA and brief TCD assessments. The primary endpoint was symptomatic intracerebral hemorrhage (sICH) within 36 hours after tPA.ResultsAmong 35 patients (Cohort 1 = 12, Cohort 2 = 11, controls = 12) no sICH occurred in Cohort 1 and controls, whereas 3 (27%, 2 fatal) sICHs occurred in Cohort 2 (p = 0.028). Sustained complete recanalization/clinical recovery rates (end of TCD monitoring/3 month) were 67%/75% for Cohort 1, 46%/50% for Cohort 2, and 33%/36% for controls (p = 0.255/0.167). The median time to any recanalization tended to be shorter in Cohort 1 (30 min; interquartile range [IQR], 6) and Cohort 2 (30 min; IQR, 69) compared to controls (60 min; IQR, 5; p = 0.054). Although patients with sICH had similar screening and pretreatment systolic blood pressure (SBP) levels in comparison to the rest, higher SBP levels were documented in sICH+ patients at 30 minutes, 60 minutes, 90 minutes, and 24–36 hours following tPA bolus.InterpretationPerflutren lipid μS can be safely combined with systemic tPA and ultrasound at a dose of 1.4ml. Safety concerns in the second dose tier may necessitate extended enrollment and further experiments to determine the mechanisms by which microspheres interact with tissues. In both dose tiers, sonothrombolysis with μS and tPA shows a trend toward higher early recanalization and clinical recovery rates compared to standard intravenous tPA therapy. Ann Neurol 2009;66:28–38

17 Mar 2009·CirculationQ1 · MEDICINE

Diagnostic Ultrasound Combined With Glycoprotein IIb/IIIa–Targeted Microbubbles Improves Microvascular Recovery After Acute Coronary Thrombotic Occlusions

Q1 · MEDICINE

Article

Author: Matsunaga, Terry ; Lof, John ; Xie, Feng ; Porter, Thomas R. ; Zutshi, Reena

Background— The high mechanical index (MI) impulses from a diagnostic ultrasound transducer may be a method of recanalizing acutely thrombosed vessels if the impulses are applied only when microbubbles are channeling through the thrombus. Methods and Results— In 45 pigs with acute left anterior descending thrombotic occlusions, a low-MI pulse sequence scheme (contrast pulse sequencing) was used to image the myocardium and guide the delivery of high-MI (1.9 MI) impulses during infusion of either intravenous platelet-targeted microbubbles or nontargeted microbubbles. A third group received no diagnostic ultrasound and microbubbles. All groups received half-dose recombinant prourokinase, heparin, and aspirin. Contrast pulse sequencing examined replenishment of contrast within the central portion of the risk area and guided the application of high-MI impulses. Angiographic recanalization rates, resolution of ST-segment elevation on ECG, and wall thickening were analyzed. Pigs receiving platelet-targeted microbubbles had more rapid replenishment of the central portion of the risk area (80% versus 40% for nontargeted microbubbles; P =0.03) and higher epicardial recanalization rates (53% versus 7% for prourokinase alone; P =0.01). Replenishment of contrast within the risk area (whether with platelet-targeted microbubbles or nontargeted microbubbles) was associated with both higher recanalization rates and even higher rates of ST-segment resolution (82% versus 21% for prourokinase alone; P =0.006). ST-segment resolution occurred in 6 pigs (40%) treated with microbubbles who did not have epicardial recanalization, of which 5 had recovery of wall thickening. Conclusions— Intravenous platelet-targeted microbubbles combined with brief high-MI diagnostic ultrasound impulses guided by contrast pulse sequencing improve both epicardial recanalization rates and microvascular recovery.

News (Medical) associated with ImaRx Therapeutics, Inc.

30 Apr 2021

·www.biospace.com

NuvOx Completes Construction of Expanded Manufacturing Facility.

April 30, 2021 10:00 UTC TUCSON, Ariz.--(BUSINESS WIRE)-- NuvOx Pharma has completed construction and initiated operation of its GMP production facility for manufacturing its injectable pharmaceutical products at its Tucson, Arizona facility. Construction of the GMP facility was financed by ImaRx Investments, LLC. The facility comprises an 1,800 square foot hard shell exterior space addition to the existing building located at 1635 East 18th Street. A 900 square foot ISO 5 cleanroom is housed within the exterior space. Olivia Longacre, Chief Operating Officer of NuvOx, oversaw construction of the exterior space and installation of the cleanroom. Olivia Longacre said, “This same ISO 5 modular cleanroom, manufactured by Terra Universal, has been successfully used by large and small pharmaceutical companies to manufacture pharmaceutical products commercially. It is our goal to manufacture our lead product, NanO2TM, for pivotal clinical trials and commercial supply after FDA approval. We have invested in our Quality Management System intended to meet all FDA regulatory requirements.” Jon Saxe, BSChE, JD, LLM, Board Member of NuvOx and former Chairman of the Mobilizing for Quality Task Force responsible for corporate oversight of quality at Hoffman La Roche Inc., said, “I am impressed with the knowledge and commitment to quality of the staff at NuvOx and their capability to successfully execute on their manufacturing program.” Evan Unger, MD, co-Founder and CEO of NuvOx, added, “We have active Phase IIb programs for NanO2 in ischemic stroke and brain cancer following successful phase Ib/II studies in both of these indications. Our own manufacturing facility allows us to control costs, maintain continuous quality improvement and support our clinical development programs.” NuvOx Pharma is a privately held biotech company based in Tucson, Arizona. For further information, visit or contact Evan Unger, MD at eunger@nuvoxpharma.com. Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise. View source version on businesswire.com: Contacts Evan Unger, MD eunger@nuvoxpharma.com Source: NuvOx Pharma View this news release online at:

24 Sep 2008

·www.biospace.com

ImaRx Therapeutics Divests Urokinase Franchise to Microbix Biosystems Inc.

TUCSON, Ariz., Sept. 24, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (NasdaqCM:IMRX - News) today announced that it has divested its urokinase business to Microbix Biosystems, Inc. (Toronto:MBX.TO - News). Through this transaction, Microbix has acquired the remaining urokinase inventory and related assets and has assumed full responsibility for ongoing commercial and regulatory activities associated with the product. Urokinase is an FDA-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism. ImaRx acquired an approximate four year inventory of the product from Abbott Laboratories and has been selling the product since 2006. Under terms of the agreement, Microbix acquired the urokinase inventory, regulatory filings and related assets for an upfront payment of $2 million and the assumption of $500,000 in chargeback liabilities for commercial product currently in the distribution channel. An additional $2.5 million payment will be made to ImaRx upon release by the FDA of the three lots of urokinase that are currently subject to a May 2008 Approvable Letter. Bradford A. Zakes, President and CEO of ImaRx, stated, ``We are pleased to have completed this transaction with Microbix. Their in-depth knowledge of this product and biologics manufacturing expertise uniquely positions them to provide long-term support for this medically important product in the marketplace.'' ImaRx intends to utilize the proceeds from this transaction to fund operations as it continues to evaluate strategic alternatives pertaining to its SonoLysis program and other corporate assets. About ImaRx Therapeutics ImaRx Therapeutics is a biopharmaceutical company that has been focused on the research, development and commercialization of therapies for vascular disorders. The Company's research and development efforts have been primarily focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts were focused on its product, urokinase, for the treatment of acute massive pulmonary embolism. The ImaRx Therapeutics, Inc. logo is available at About SonoLysis ImaRx's SonoLysis program involves the administration of its proprietary MRX-801 microbubbles and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The sub-micron size of MRX-801 microbubbles enables them to penetrate a blood clot, so that when ultrasound is applied their expansion and contraction, or cavitation, results in a disruption of the clot into very small particles. This technology was most recently evaluated in a Phase I/II clinical trial in combination with tPA in patients suffering from acute ischemic stroke. About Urokinase Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercialized for more than 20 years and has been administered to greater than four million patients. In 2006, ImaRx acquired urokinase and all related assets, including an approximate four-year supply of inventory, cell lines and manufacturing rights to the drug. Since October 2006, ImaRx has been selling its urokinase inventory in the U.S. market where it is estimated to be listed on pharmacy formularies at approximately 700 acute care hospitals. Cautionary Statement For The Purpose Of The ``Safe Harbor'' Provisions Of The Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including: the FDA may not approve the release of the 3 lots of urokinase and as a result ImaRx will not receive the additional $2.5 million payment; ImaRx may not timely or successfully develop SonoLysis; the Company may not have sufficient resources to complete the development of SonoLysis for any indication; and other risks associated with the approval and commercialization of the technologies. These forward-looking statements represent ImaRx's judgment as of the date of this press release. Additional risks and uncertainties related to ImaRx can be found in its filings with the U.S. Securities and Exchange Commission. This press release is as of September 24, 2008 and the Company disclaims any intent or obligation to update these forward-looking statements. Contact: ImaRx Therapeutics, Inc. Bradford A. Zakes, President & CEO (520) 770-1259 bzakes@imarx.com Source: ImaRx Therapeutics, Inc.

05 Nov 2007

·www.biospace.com

ImaRx Therapeutics and Royal Philips Electronics N.V. to Collaborate on Potential Treatment for Ischemic Stroke Using Microbubbles and Ultrasound

TUCSON, Ariz. & ANDOVER, Mass.--(BUSINESS WIRE)--ImaRx Therapeutics, Inc. (Nasdaq: IMRX) and Royal Philips Electronics (NYSE: PHG) (AEX: PHI) today announced a research collaboration to evaluate Philips ultrasound technology as part of ImaRx’s SonoLysis™ program to develop new treatment for acute ischemic stroke. Under the agreement, Philips’ Medical Systems division will provide ultrasound devices and technical assistance to ImaRx during laboratory and preclinical studies. The objective of the collaboration is to determine the optimal ultrasound parameters to use with ImaRx’s proprietary MRX-801 microbubble technology.

Collaborate

100 Deals associated with ImaRx Therapeutics, Inc.

100 Translational Medicine associated with ImaRx Therapeutics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 04 Oct 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Alteplase/microbubble combination therapeutic(ImaRx Therapeutics) ( PLG )	-	Discontinued
MRX-951 ( Tubulin )	Neoplasms More	Discontinued
MRX-960	Neoplasms More	Pending
MRX-820	Stroke More	Pending
MRX-952	Pain More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis